Status
|
In progress
|
Process |
STA 2018
|
ID number |
916
|
Provisional Schedule
Final appraisal document |
28 November 2019 - 12 December 2019 |
Expected publication |
15 January 2020 |
Project Team
Project lead |
Thomas Feist |
Email enquiries
Evidence Review Group / Assessment Group |
Liverpool Reviews and Implementation Group, University of Liverpool |
Consultees
Companies sponsors |
Pfizer |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Breast Cancer Care |
|
Breast Cancer Now |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
UK Breast Cancer Group |
Commentators
Comparator companies |
Eli Lilly |
|
Novartis |
|
Roche Products |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Department of Health, Social Services and Public Safety - Northern Ireland |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Date
|
Update
|
10 October 2019
|
Committee meeting: 1 |
08 February 2019
|
Invitation to participate |
31 December 2018 - 23 January 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
30 November 2018
|
In progress, Following publication of TA495 this appraisal will now restart. The timelines for this appraisal have been set in order that key overall survival data can be included in the company’s submission. The first committee meeting will take place in October 2019. |
03 February 2017
|
Suspended, Pfizer has indicated that they will not be making a submission to NICE for the above indication until the outcome of the palboclicib plus an aromatase inhibitor appraisal [ID915] is final. In the meantime appraisal [ID916] will be suspended while NICE considers the options for rescheduling. |
23 November 2016
|
The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has now been rescheduled. The first committee meeting will take place in June 2017. |
20 October 2016
|
The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has been suspended at the request of Pfizer. The Company submission of a value proposition for palbociclib after endocrine therapy will follow after the outcome of the appraisal of palbociclib for previously untreated disease [ID915] is known. |
06 October 2016
|
Invitation to participate |
13 May 2016
|
Referral |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance